💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ibandronic Acid

CHEMBL997 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
319.2 g/mol
LogP
-4.1
Phase
4

This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.

분자량

319.2300 g/mol

LogP

-4.10

TPSA

139.00 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Systemic Lupus Erythematosus Type 2 Diabetes Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

작용 기전

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H23NO7P2

                    

                    
                    

                        
HBD / HBA

                        
5 / 8

                    

                    
                    

                        
회전 가능 결합

                        
9

                    

                    
                    
                    

                        
무거운 원자

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This is the acid form of ibandronate, a bisphosphonate medication that prevents bone loss by inhibiting the bone-resorbing activity of osteoclasts. It is used to treat osteoporosis, reduce fracture risk, and manage hypercalcemia of malignancy and bone metastases. Patients taking oral forms should remain upright after swallowing to minimize esophageal irritation.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ibandronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL997.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 60852.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.